Artelo Biosciences (ARTL)
Develops cannabinoid and fatty-acid-binding-protein drug candidates for cancer supportive care and pain.
Something off on this page? Send us feedback.
Develops prescription drug candidates that modulate cannabinoid receptors and fatty-acid-binding proteins, with ART27.13, ART26.12 and ART12.11 spanning cancer supportive care, pain and neuropsychiatric research. It has no marketed products and relies on outsourced development and licensed intellectual property.
Develops small-molecule medicines that modulate lipid signaling, particularly cannabinoid receptors and fatty-acid-binding proteins, for regulated prescription treatment of unmet needs. Its portfolio includes ART27.13 for cancer-related anorexia/cachexia and glaucoma or ocular hypertension, ART26.12 for chemotherapy-induced peripheral neuropathy and related research, and ART12.11, an oral cannabidiol-tetramethylpyrazine cocrystal under preclinical study.
Operates from the United States with subsidiaries, collaborators and clinical activity across the United Kingdom, Ireland, Canada and other countries. Development is conducted through employees, consultants, clinical investigators and contract research and manufacturing organizations; the company owns no laboratories or manufacturing facilities. ART27.13 and the FABP platform depend on exclusive licenses that carry diligence, milestone and royalty obligations.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.2M · Total debt $49.0K · Total assets $6.5M · Shareholders' equity $5.0M
- Revenue
- $0
- Operating income
- −$2.5M
- Net income
- −$2.4M
No dividends on record.
| Institutions | 3.36% | 13.0K shares | |
|---|---|---|---|
| 10 holders · as of Jun 30, 2026 | |||
| Other | 96.64% | 374.3K shares | |
| remainder | |||
387.3K company shares as of Sep 1, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jane Street Group, LLCInstitution | 1.90% | 66,341 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.40% | 13,864 | as of Jun 30, 2026 |
Stonex Group Inc.Institution | 0.36% | 12,400 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.29% | 10,129 | as of Jun 30, 2026 |
Tower Research Capital LLC (TRC)Institution | 0.24% | 8,435 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Pfizer
Advanced cancer-cachexia program targeting weight loss and anorexia.
- Jazz Pharmaceuticals
Prescription cannabidiol benchmark for the oral-CBD formulation field.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Artelo Biosciences | $4.02 | −1.95% | $1.6M | — | — | — | — |
| Pfizer | $27.92 | +0.64% | $158.10B | 36.7 | 10.0 | 2.5 | +2.6% |
| Jazz Pharmaceuticals | $241.46 | −0.00% | $15.17B | 16.5 | 9.6 | 3.3 | +15.6% |
| Median | 26.6 | 9.8 | 2.9 | +9.1% |